Schedule a meeting to discuss your complex biologic or bioconjugate program with our experts during DCAT Week 2025 , March 17-20.

Schedule some time to connect on your project-specific needs and we can provide you with an update on our expanded global capabilities. From antibodies (mAbs) to recombinant vaccines and bioconjugates including antibody-drug conjugates (ADCs), radioconjugates, and oligonucleotides, our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone.

About Abzena

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. We have research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.